Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder

被引:12
|
作者
Lees, Rachel [1 ]
Hines, Lindsey A. A. [3 ]
Hindocha, Chandni [4 ]
Baio, Gianluca [5 ]
Shaban, Natacha D. C. [6 ]
Stothart, George [2 ]
Mofeez, Ali [7 ]
Morgan, Celia J. A. [8 ]
Curran, H. Valerie [4 ]
Freeman, Tom P. P. [1 ]
机构
[1] Univ Bath, Dept Psychol, Addict & Mental Hlth Grp, Bath, England
[2] Univ Bath, Dept Psychol, Bath, England
[3] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, England
[4] UCL, Clin Psychopharmacol Unit, London, England
[5] UCL, Dept Stat Sci, London, England
[6] Univ Oxford, Oxford, England
[7] UCLH, Natl Hosp Neurol & Neurosurg, Pain Management Ctr, London, England
[8] Univ Exeter, Psychopharmacol & Addict Res Ctr, Exeter, England
基金
英国医学研究理事会;
关键词
Cannabidiol; Cannabis use disorder; Clinical trial; Cognition; Verbal learning and memory; MEMORY; SYMPTOMS; INTERVENTION; CBD;
D O I
10.1007/s00213-022-06303-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale:Chronic cannabis use is associated with impaired cognitive function. Evidence indicates cannabidiol (CBD) might be beneficial for treating cannabis use disorder. CBD may also have pro-cognitive effects; however, its effect on cognition in people with cannabis use disorder is currently unclear. Objectives:We aimed to assess whether a 4-week CBD treatment impacted cognitive function. We hypothesised that CBD treatment would improve cognition from baseline to week 4, compared to placebo. Methods:Cognition was assessed as a secondary outcome in a phase 2a randomised, double-blind, parallel-group and placebo-controlled clinical trial of 4-week daily 200 mg, 400 mg and 800 mg CBD for the treatment of cannabis use disorder. Participants had moderate or severe DSM-5 cannabis use disorder and intended to quit cannabis use. Our pre-registered primary cognitive outcome was delayed prose recall. Secondary cognitive outcomes were immediate prose recall, stop signal reaction time, trail-making task performance, verbal fluency and digit span. Results:Seventy participants were randomly assigned to placebo (n = 23), 400 mg CBD (n = 24) and 800 mg CBD (n = 23). A 200 mg group was eliminated from the trial because it was an inefficacious dose at interim analysis (n = 12) and was not analysed here. For the primary cognitive outcome, there was no effect of CBD compared to placebo, evidenced by a lack of dose-by-time interaction at 400 mg (0.46, 95%CIs: - 1.41, 2.54) and 800 mg (0.89, 95%CIs: - 0.99, 2.81). There was no effect of CBD compared to placebo on secondary cognitive outcomes, except backwards digit span which increased following 800 mg CBD (0.30, 95%CIs: 0.02, 0.58). Conclusions:In this clinical trial for cannabis use disorder, CBD did not influence delayed verbal memory. CBD did not have broad cognitive effects but 800 mg daily treatment may improve working memory manipulation.
引用
收藏
页码:337 / 346
页数:10
相关论文
共 37 条
  • [31] Clinical outcomes and cost-effectiveness of brief guided parent-delivered cognitive behavioural therapy and solution-focused brief therapy for treatment of childhood anxiety disorders: a randomised controlled trial
    Creswell, Cathy
    Violato, Mara
    Fairbanks, Hannah
    White, Elizabeth
    Parkinson, Monika
    Abitabile, Gemma
    Leidi, Alessandro
    Cooper, Peter J.
    LANCET PSYCHIATRY, 2017, 4 (07): : 529 - 539
  • [32] Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement Findings From the EXTEND Study
    Strom, Jordan B.
    Faridi, Kamil F.
    Butala, Neel M.
    Zhao, Yuansong
    Tamez, Hector
    Valsdottir, Linda R.
    Brennan, J. Matthew
    Shen, Changyu
    Popma, Jeffrey J.
    Kazi, Dhruv S.
    Yeh, Robert W.
    CIRCULATION, 2020, 142 (03) : 203 - 213
  • [33] Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper
    Armeni, Kelsey
    Chambers, Laura C.
    Peachey, Alyssa
    Berk, Justin
    Langdon, Kirsten J.
    Peterson, Lisa
    Beaudoin, Francesca L.
    Wightman, Rachel S.
    BMJ OPEN, 2024, 14 (11): : e085888
  • [34] A parallel 3-group randomised clinical trial comparing different implant treatment options for the edentulous mandible: 1-year effects on dental patient-reported outcomes and chewing function
    Hartmann, Roberto
    Freitas de Menezes Bandeira, Ana Clara
    de Araujo, Sara Cristina
    Braegger, Urs
    Schimmel, Martin
    Leles, Claudio Rodrigues
    JOURNAL OF ORAL REHABILITATION, 2020, 47 (10) : 1264 - 1277
  • [35] d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and Post Hoc Effect Size Analyses from a Pivotal Trial
    Cutler, Andrew J.
    Suzuki, Katsumi
    Starling, Brittney
    Balakrishnan, Kanan
    Komaroff, Marina
    Meeves, Suzanne
    Castelli, Mariacristina
    Childress, Ann
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2023, 33 (05) : 176 - 182
  • [36] Is a Severe Clinical Profile an Effect Modifier in a Web-Based Depression Treatment for Adults With Type 1 or Type 2 Diabetes? Secondary Analyses From a Randomized Controlled Trial
    van Bastelaar, Kim M. P.
    Pouwer, Francois
    Cuijpers, Pim
    Riper, Heleen
    Twisk, Jos W. R.
    Snoek, Frank J.
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2012, 14 (01)
  • [37] Effect of multivitamin-mineral supplementation versus placebo on cognitive function: results from the clinic subcohort of the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial and meta-analysis of 3 cognitive studies within COSMOS
    Vyas, Chirag M.
    Manson, JoAnn E.
    Sesso, Howard D.
    Cook, Nancy R.
    Rist, Pamela M.
    Weinberg, Alison
    Moorthy, M. Vinayaga
    Baker, Laura D.
    Espeland, Mark A.
    Yeung, Lok-Kin
    Brickman, Adam M.
    Okereke, Olivia, I
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2024, 119 (03) : 692 - 701